An Early- and Late-Stage Convolution Model for Disease Natural History

Biometrics

Volumn 60, Issue 1, 2004, Pages 191-198

  Pinsky, Paul F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Lead time; Natural history; Screening; Stage

Indexed keywords

CONVOLUTION; DIAGNOSIS; MAXIMUM LIKELIHOOD;

CANCER; CLINICAL STATE; CONVOLUTION MODEL; LATE STAGE; LEADTIME; MA XIMUM LIKELIHOODS; MAXIMUM-LIKELIHOOD; NATURAL HISTORY; SCREENING PROGRAMS; SOJOURN TIME;

DISEASES;

CANCER; EPIDEMIOLOGY; STATISTICAL ANALYSIS;

ARTICLE; BIOMETRY; CALCULATION; CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HISTORY; MATHEMATICAL ANALYSIS; METASTASIS; STANDARD; STATISTICAL MODEL; TIME;

BIKINIA LE-TESTUI;

EID: 1642286684     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.2004.00023.x     Document Type: Article

References (12)

1. Auvin, A., Maattanen, L., Stenman, U. H., Tammela, T., Rannikko, S., Aro, J., Juusela, H., and Hakama, H. (2002). Lead-time in prostate cancer screening (Finland). Cancer Causes and Control 13, 279-285.
2. Bamber, D. and van Santen, J. P. H. (2000). How to assess a model's testability and identifiability. Journal of Mathematical Psychology 44, 20-40.
3. Chen, H. H., Duffy, S. W., and Tabar, L. (1996). A Markov chain method to estimate the tumor progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. The Statistician 45, 307-317.
4. Chen, H. H., Kuo, H. S., Yen, M. F., Lai, M. S., Tabar, L., and Duffy, S. W. (2000). Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 56, 167-172.
5. Church, T. (2003). Simulated screening for prostate cancer: The useful model. Journal of the National Cancer Institute 95, 838-839.
6. Day, N. E. and Walter, S. D. (1984). Simplified models of screening for chronic disease: Estimation procedures from mass screening programmes. Biometrics 40, 1-14.
7. Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., and de Koning, H. J. (2003). Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute 95, 868-877.
8. Fontana, R. S., Sanderson, D. R., Taylor, W. F., Woolner, L. B., Miller, E., Muhm, J. R., and Uhlenhopp, M. (1984). Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study. American Review of Respiratory Disease 130, 561-565.
9. Fontana, R. S., Sanderson, D. R., Woolner, L. B., Taylor, W. F., Miller, E., and Muhm., J. R. (1986). Lung cancer screening: The Mayo program. Journal of Occupational Medicine 28, 746-750.
10. Paci, E. and Duffy, S. W. (1991). Modeling the analysis of breast cancer screening programmes: Sensitivity, lead time and predictive value in the Florence district programme (1975-1986). International Journal of Epidemiology 20, 852-858.
11. Pinsky, P. (2001). Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics 57, 389-395.
12. van der Maas, P. J., de Koning, H. J., van Ineveld, B. M., van Oortmartssen, G. J., Habbema, J. D., Lubbe, K. T., Geerts, A. T., Collette, H. J., Verbeek, A. L., and Hendriks, J. H. (1989). The cost-effectiveness of breast cancer screening. International Journal of Cancer 43, 1055-1060.